Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb CofiledCriticalBristol Myers Squibb Co
Priority to JOP/2019/0286ApriorityCriticalpatent/JOP20190286A1/en
Publication of JOP20190286A1publicationCriticalpatent/JOP20190286A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Dosage regimens and formulations of anti-human tau antibodies are provided. These formulations and dosage regimens find use in the treatment of tauopathies such as progressive supranuclear palsy and Alzheimer's disease. Fig. 8
JOP/2019/0286A2018-12-162018-12-16Compositions and methods for treating tauopathies
JOP20190286A1
(en)